European Urology Oncology A Multicentre Analysis of the Detection of Clinically Significant Prostate Cancer Following Transperineal Image-fusion Targeted and Nontargeted Systematic Prostate Biopsy in Men at Risk  Saiful Miah, Feargus Hosking-Jervis, Martin J. Connor, David Eldred-Evans, Taimur T. Shah, Manit Arya, Neil Barber, Jeetesh Bhardwa, Simon Bott, Daniel Burke, Alan Doherty, Christopher Foster, Alex Freeman, Richard Hindley, Charles Jameson, Omer Karim, Marc Laniado, Bruce Montgomery, Raj Nigam, Shonit Punwani, Andrew Sinclair, Mathias Winkler, Clare Allen, Hashim U. Ahmed  European Urology Oncology  DOI: 10.1016/j.euo.2019.03.005 Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 1 Detection rates for clinically significant and insignificant cancers between targeted and combination (targeted+nontargeted) biopsies (n=640 in each group), with clinically significant disease according to: (A) UCL/Ahmed definition 1 (Gleason≥4+3 or any grade ≥6mm); (B) UCL/Ahmed definition 2 (Gleason≥3+4 or any grade ≥4mm); and (C) Gleason≥3+4=7. European Urology Oncology DOI: (10.1016/j.euo.2019.03.005) Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 2 Rates of detection of clinically significant, insignificant, and no cancer for magnetic resonance imaging-detected lesions with Likert scores of 3–5. Clinically significant disease: UCL/Ahmed definition 1 (Gleason≥4+3 or any grade ≥6mm). European Urology Oncology DOI: (10.1016/j.euo.2019.03.005) Copyright © 2019 European Association of Urology Terms and Conditions